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Abstract
The efficacy of pyrimethamine-sulfadoxine in the treatment of uncomplicated falciparum malaria in
young children of a malaria holoendemic area in rural Burkina Faso is reported. Of 28 children
treated with a standard single dose of pyrimethamine-sulfadoxine and followed-up over 14 days,
only one Late Treatment Failure and four Late Parasitological Failures were observed, all with low-
grade parasitaemia. In this area of very restricted use of pyrimethamine-sulfadoxine, the drug
appears to be still sufficiently effective in the treatment of malaria. These findings provide further
evidence for the justification of continued use of pyrimethamine-sulfadoxine as a second-line
treatment for malaria in Burkina Faso.
Background
The first cases of in vitro and in vivo chloroquine resistance
in Burkina Faso were seen in 1983 and 1988, respectively,
and reported clinical failure rates after use of chloroquine
for treatment of uncomplicated malaria in children were
already around 5% in the early 1990s [1]. More recently,
the clinical failure rate of chloroquine in pre-school chil-
dren was shown to be around 10% in western Burkina
Faso [2,3]. These findings have led to the conclusion that
chloroquine still remains sufficiently effective after many
years of resistance occurrence in this part of West Africa.
Little information exists on the dynamics of resistance
development towards pyrimethamine-sulfadoxine, the
usual second-line treatment choice in African countries
with moderate chloroquine resistance. In Burkina Faso,
only very low parasitological and clinical failure rates dur-
ing use of have been reported in the past [1,2].
The efficacy of pyrimethamine-sulfadoxine in a rural area
of north-western Burkina Faso is reported.
Methods
The study took place in six representative villages of the
research area of the Centre de Recherche en Santé de Nouna
(CRSN) in north-western Burkina Faso [4]. The Nouna
area is a dry orchard savanna, populated mainly by sub-
sistence farmers of different ethnic groups. Malaria is
holoendemic but highly seasonal in the study area [4].
The study was nested into an ongoing insecticide-treated
bed net (ITN) study [5]. All ITN cohort children from the
six villages visited during a cross-sectional survey in Octo-
ber 2002 were enrolled if they fulfilled the following
inclusion criteria: age >6 months, falciparum malaria
(≥37.5°C axillary temperature + ≥2.000 Plasmodium falci-
parum parasites/µl blood in the absence of another obvi-
ous fever cause), absence of antimalarial treatment during
previous two weeks, informed oral consent. All study chil-
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dren received a fully supervised single-drug treatment
with 1/2 tablet Fansidar (12.5 mg pyrimethamine plus
250 mg sulfadoxine), taken from the essential drug stock
of Nouna Health District. Children were observed for an
hour after treatment. In the event of vomiting, they
received another 1/2 tablet Fansidar.
Enrolled children were seen daily by village-based field
staff over a 14-day period and, in case of fever (≥37.5°C
axillary temperature), blood films were taken. Systematic
blood slides were taken from all study children on day 0,
3, 7 and 14. Blood films were examined by two experi-
enced laboratory technicians of the CRSN.
For the evaluation of treatment outcome, a modified def-
inition of the WHO protocol for assessment of therapeutic
efficacy of anti-malarial drugs in areas with intense trans-
mission was used [6]. Early Treatment Failure (ETF) was
defined as development of severe malaria on days 1–3 or
axillary temperature ≥37.5°C on day 3 in the presence of
parasitaemia, and Late Treatment Failure (LTF) as devel-
opment of severe malaria and/or axillary temperature
≥37.5°C on days 4–14 in the presence of parasitaemia
without previously meeting the criteria of ETF. Late Para-
sitological Failure (LPF) was defined as the presence of
parasitaemia on day 7 and/or day 14. Approval for the
study was granted by the Ethical Committee of the Heidel-
berg University Medical School and the Ministry of Health
in Burkina Faso.
Results
Of 357 cohort children seen during the survey, 40 chil-
dren (11%) were febrile and of those only 4 children had
no detectable malaria parasitaemia. Overall, 28 children
met the inclusion criteria and were enrolled into the
study. At baseline, the mean age of these study children
was 23 months (range 9–32), 17/28 (61%) were male, the
mean temperature was 38.1°C (range 37.5–39.9), and the
mean weight was 9.5 kg (range 5.5–12.9). The median
baseline number of P. falciparum trophozoites was
13.100/µl (range 2.000–177.000), and 9/28 (32%) study
children had P. falciparum gametocytes on day 0.
There was no loss to follow-up. No ETF was observed and
only one LTF occurred in a 26 months old and 10.0 kg
weighing male child, who had fever (38.7°C) and a low-
grade parasitaemia (50/µl) on day 14. In addition, 7/28
(25%) study children still had measurable parasitaemia
on day 3 (50–475/µl) without fever, and 4/28 (14%)
study children had a LPF with low-grade parasitaemias
(75–250/µl), two on day 7 and two on day 14 (all male).
On day 7 and/or day 14, P. falciparum gametozytes were
seen in 19/28 (68%) of study children.
Discussion
The findings from this study confirm the still very low
level of resistance to pyrimethamine-sulfadoxine in West
Africa [2,7-9]. The likely reason for the continued efficacy
of pyrimethamine-sulfadoxine is the low level of drug
pressure in these areas, where the large majority of malaria
cases is still treated with chloroquine [10]. These findings
justify continued use of pyrimethamine-sulfadoxine for
malaria second-line treatment in Burkina Faso, as in most
of West Africa.
However, the question of which drug or drug combina-
tion should be the successor of chloroquine for malaria
first-line treatment once this has reached unacceptable
high failure rates remains largely unsolved for the poor
malaria-endemic countries in sub-Saharan Africa (SSA)
[11,12]. Although, with regard to its still high efficacy,
pyrimethamine-sulfadoxine would be a promising candi-
date for replacing chloroquine in West Africa, resistance is
predicted to occur rapidly when the drug is used alone
[11,13]. Artemisinin combination therapy (ACT) is now
recommended by the World Health Organization as a
first-line treatment for malaria, but these combinations
are comparably very expensive and their use in malaria
control programmes will thus not be possible in many
countries of SSA without sustainable external support
[11,14]. The combination of amodiaquine and pyrimeth-
amine-sulfadoxine has recently been shown to be even
more effective than ACT, and this combination has now
been chosen as a pragmatic interim solution by some
countries of SSA [15,16]. Finally, the implications on the
long-term effectiveness of intermittent pyrimethamine-
sulfadoxine preventive treatment during pregnancy need
to be taken seriously into consideration when using
pyrimethamine-sulfadoxine as a first-line malaria therapy
regimens in SSA [17].
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